news25 May 2021 | By Hannah Balfour (European Pharmaceutical Review)
JadiCell™ was shown to significantly improve survival in COVID-19 patients with Acute Respiratory Distress Syndrome (ARDS) and also reduce lung scarring associated with long-COVID-19.